Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Prostate cancer

Combination of vaccine plus ipilimumab—safety and toxicity

Nature Reviews Urology volume 9, pages 302–303 (2012)Cite this article

Subjects

Cytotoxic lymphocyte antigen-4 (CTLA-4) blockade plus vaccine as a combination therapy strategy to promote the immune response to cancer has demonstrated similar toxicities to anti-CTLA-4 monotherapy. As anti-CTLA-4 therapy has demonstrated clinical efficacy, continued exploration and optimization is warranted and must include investigations of combination strategies and management of adverse events.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Krummel, M. F. & Allison, J. P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182, 459–465 (1995).

    Article  CAS  Google Scholar 

  2. Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 71, 1734–1736 (1996).

    Article  Google Scholar 

  3. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).

    Article  CAS  Google Scholar 

  4. Sharma, P., Wagner, K., Wolchok, J. D. & Allison, J. P. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat. Rev. Cancer 11, 805–812 (2011).

    Article  CAS  Google Scholar 

  5. Van Elsas, A., Hurwitz, A. A. & Allison, J. P. Combination immunotherapy of B16 melanoma using anti-cytotoxic lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190, 355–366 (1999).

    Article  CAS  Google Scholar 

  6. Madan, R. A. et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. http://dx.doi.org/10.1016/S1470-2045(12)70006-2.

  7. van den Eertwegh, A. J. et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. http://dx.doi.org/10.1016/S1470-2045(12)70007-4.

  8. Buchman, A. L. Side effects of corticosteroid therapy. J. Clin. Gastroenterol. 33, 289–294 (2001).

    Article  CAS  Google Scholar 

  9. Di Giacomo, A. M., Biagiolo, M. & Maio, M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin. Oncol. 37, 499–507 (2010).

    Article  CAS  Google Scholar 

  10. Bow, E. J. Management of the febrile neutropenic cancer patient: lessons from 40 years of study. Clin. Microbiol. Infect. 11 (Suppl. 5), 24–29 (2005).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Immunology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1374, Houston, 77030, TX, USA

    Padmanee Sharma

  2. Genitourinary Medical Oncology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1374, Houston, 77030, TX, USA

    Christopher Logothetis

Authors
  1. Padmanee Sharma
    View author publications

    Search author on:PubMed Google Scholar

  2. Christopher Logothetis
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Padmanee Sharma.

Ethics declarations

Competing interests

P. Sharma and C. Logothetis have acted as consultants for Bristol–Myers Squibb and Dendreon.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sharma, P., Logothetis, C. Combination of vaccine plus ipilimumab—safety and toxicity. Nat Rev Urol 9, 302–303 (2012). https://doi.org/10.1038/nrurol.2012.103

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrurol.2012.103

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing